Nobel laureate heads up NCI

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 6
Volume 19
Issue 6

Harold E. Varmus, MD, has been nominated by President Barack Obama to serve as the director of the NCI.

Harold E. Varmus, MD, has been nominated by President Barack Obama to serve as the director of the NCI. Dr. Varmus most recently served as president and CEO of Memorial Sloan-Kettering Cancer Center in New York. Dr. Varmus, J. Michael Bishop, MD, and colleagues won the 1989 Nobel Prize for Physiology or Medicine when they demonstrated the cellular origins of the oncogene of a chicken retrovirus. This led to the isolation of cellular genes that control growth and development and are frequently mutated in human cancer. The NCI directorship will be Dr. Varmus' second go-round heading up a federal institution: He served as director of the NIH from 1993 to 1999.

Articles in this issue
Nobel laureate heads up NCI
Cleveland Clinic nets federal funds for research facility revamp
Diabetes drug acts as chemopreventive in smokers
FTC extends deadline for Red Flags Rule on patient privacy
From the ONI archives: Ofatumumab turns in encouraging results in pretreated CLL
Studies strengthen connection between mammographic breast density and a woman’s risk of breast cancer
Excess weight, smoking may influence risk of disease relapse after prostate cancer treatment
Breakthrough cancer-related pain: The truth hurts
African-American genetic mutations pose Rx challenge
African-American genetic mutations pose Rx challenge
Personalized medicine advances in non-small–cell lung cancer treatment
PET unable to reliably identify post-Rx colon mets
Medicare study questions use of high-tech cancer imaging
Who's News
Recent Videos
7 experts are featured in this series.
7 experts are featured in this series.
In the SWOG S2409 PRISM trial, over 800 patients with small cell lung cancer will receive different treatment regimens based on their disease subtype.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
Data from the phase 3 evERA trial show a trend towards improved overall survival with giredestrant plus everolimus in this breast cancer population.

Giredestrant Combo Significantly Boosts PFS in ER+ Advanced Breast Cancer

Russ Conroy
September 22nd 2025
Article

Data from the phase 3 evERA trial show a trend towards improved overall survival with giredestrant plus everolimus in this breast cancer population.

How To Discuss Death? A Conversation of Mortality in Cancer Care

How To Discuss Death? A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO, and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.

Cytokine release syndrome occurred in 36.1% of patients, with 22.2% being grade 1 and 13.9% being grade 2.

Is There Space for Single-Agent Mosunetuzumab in Frontline MZL Care?

Tim Cortese
September 22nd 2025
Article

Results from the phase 2 MorningSun trial demonstrated that outpatient, subcutaneous single-agent mosunetuzumab was efficacious in patients with marginal zone lymphoma.

Panelists and presenters attending World GU 2025 shared their perspectives on optimizing the management of prostate, kidney, and bladder cancers.

Gathering the Latest Multidisciplinary Care Insights Across World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mehmet Asim Bilen, MD;Sid Sadler;Kerry R. Schaffer, MD;Mark T. Fleming, MD;Jeff Yorio, MD;Mike Lattanzi, MD;Elizabeth Kessler, MD;Benjamin L. Maughan, MD, PharmD;Alan Tan, MD
September 18th 2025
Podcast

Panelists and presenters attending World GU 2025 shared their perspectives on optimizing the management of prostate, kidney, and bladder cancers.

3 Things You Should Know About Data Presented at ESMO GI

3 Things You Should Know About Data Presented at ESMO GI

ONCOLOGY Staff
September 22nd 2025
Article

New therapies for hepatobiliary cancers show promise, expanding treatment options for patients with advanced disease and challenging conditions.

Regarding safety, treatment-related adverse effects occurred in 93% of patients, with grade 3 or 4 TRAEs occurring in 60%.

Mosunetuzumab Treatment Combo Yields Responses in High-Risk MCL

Tim Cortese
September 21st 2025
Article

Michael Wang, MD, stated that results from this phase 2 trial were tremendous and showed that mosunetuzumab plus polatuzumab vedotin is viable in MCL.